

Supplemental Materials for “Differential parsing of EGFR endocytic flux among parallel internalization pathways in lung cancer cells with EGFR-activating mutations,”


Alice M. Walsh and Matthew J. Lazzara

Supplemental Materials and Methods:


Cell lysis and western blotting. Whole cell lysates were prepared in a standard cell extraction buffer (Life Technologies) supplemented with protease and phosphatase inhibitors (Sigma). Lysates were cleared by centrifugation at 13,200 rpm for 10 min, and total protein concentrations were determined by micro-bicinchoninic assay (Thermo Scientific). Approximately 20 µg of total protein was loaded per lane on 4-12% gradient polyacrylamide gels (Life Technologies) under denaturing and reducing conditions and transferred to 0.2 µm nitrocellulose membranes (Life Technologies). After probing with antibodies, membranes were imaged on a LI-COR Odyssey scanner (LI-COR). Membranes were stripped with 0.2 M NaOH as needed.

Estimation of number of EGFR per cell. Recombinant human EGF (Peprotech) was labeled with ¹²⁵I as described previously.¹ Cells were starved overnight in media containing 0.1% FBS (Life Technologies) and then treated with 10 ng/mL ¹²⁵I-EGF on ice for 30 min. After washing with buffer to remove un-bound ¹²⁵I-EGF, the amount of cell surface-associated radioactivity was quantified by stripping surface-bound ligand from receptors using a mild acid strip. These samples were used to calculate the number of EGFR per cell based on the known EGF/EGFR dissociation constant and the specific activity of the labeled EGF. Three plates were reserved to determine the number of cells per plate by counting with a hemocytometer.


Supplemental Figures:




Supplemental Figure 1. Measurement of number of EGFR per cell in PC9 cells. The number of EGFR per cell in PC9 cells was calculated using ¹²⁵I-EGF binding as described in *Supplemental Materials and Methods*. Data represents the mean of three replicates ± s.d.




Supplemental Figure 2. Simulation of SPRY2 phosphorylation. SPRY2 phosphorylation with 10 ng/mL EGF treatment was simulated over the time course of an EGFR k_e measurement. Base model conditions with standard parameters for H1666 cells were used. SPRY2 phosphorylation parameters were estimated to agree with data from Mason et al.² such that peak SPRY2 phosphorylation occurred by 3 min after EGF addition.




Supplemental Figure 3. Predicted and experimental measurements of internal and surface-bound EGF for H1666 cells. The k_i parameters were fit to k_e data from H1666 cells as described in Fig. 2A. Shown here are the primary experimental data from the study by Walsh and Lazzara¹ used to experimentally determine k_e values and the ability of the model to recapitulate the dynamics of surface and internal ¹²⁵I-EGF. Markers represent the mean of three experimental replicates \pm s.d.




Supplemental Figure 4. Values of fitted rate constants for a range of MIG6 and CBL concentrations. The k_i parameters were fit to data from (A) H1666 cells or (B) PC9 cells as described in Figs. 2C and Fig. 3C. Stars indicate the base MIG6 and CBL concentrations ($[MIG6] = 5 \times 10^4 \text{ cell}^{-1}$ (H1666) or $1.2 \times 10^5 \text{ cell}^{-1}$ (PC9) and $[CBL] = 1 \times 10^5 \text{ cell}^{-1}$).




Supplemental Figure 5. EGFR internalization flux over a range of MIG6 and CBL concentrations. EGFR flux is plotted for receptors internalized by MIG6 or CBL pathways at $t = 3.5$ min or 7 min for (A) H1666 cells and (B) PC9 cells. Stars indicate the base MIG6 and CBL concentrations ($[\text{MIG6}] = 5 \times 10^4 \text{ cell}^{-1}$ (H1666) or $1.2 \times 10^5 \text{ cell}^{-1}$ (PC9) and $[\text{CBL}] = 1 \times 10^5 \text{ cell}^{-1}$).




Supplemental Figure 6. Effect of allowing basal MIG6/EGFR association on model fit to PC9 data. The k_i parameters were fit to data from PC9 cells as in Fig. 3 and then by allowing basal MIG6/EGFR association for non-ligand-bound EGFR dimers using standard MIG6 and CBL concentrations.




Supplemental Figure 7. Predicted effect of changing dimerization rate on relationship between EGFR expression and predicted EGFR k_e . For parameters fit to data from H1666 cells, k_{+dim} was set to values between 10⁻³ and 10⁻⁷ cell s⁻¹, and the predicted k_e was calculated for a range of EGFR concentrations as in Fig. 4A. This demonstrates that the increase in k_e with increasing EGFR expression arises due to an increased driving force for EGFR dimerization.



Supplemental Figure 8. Model agreement with H1666 data. Model error was calculated considering: (A) all data points with normal model conditions, (B) data excluding MIG6 knockdown data with $[MIG6] = [CBL] = 1 \times 10^5 \text{ cell}^{-1}$, $k_{on,M} = k_{on,C}$, and $k_{on,S} = 0$, and (C) the same conditions for C including all data. The log of the sum of the squares error (SSE) is plotted for a range of $k_{i,MIG6}$ and $k_{i,CBL}$. Error minima are indicated by red circles. The dashed lines represent $k_{i,MIG6} = k_{i,CBL}$.



Supplemental Figure 9. Fitted parameters when changes in EGFR expression due to SPRY2 knockdown are not considered. The k_i parameters were fit to experimental EGFR k_e data for controls, MIG6 knockdown, and SPRY2 knockdown from H1666 or PC9 cells using standard MIG6 and CBL concentrations as described for Figs. 2 and 3. The k_i parameters were also fit without changing EGFR concentration for SPRY2 knockdown conditions.



Supplemental Figure 10. Values of fitted rate constants when f_r was set to experimentally determined values. The k_i parameters were fit to all data points from H1666 or PC9 cells using standard MIG6 and CBL concentrations ($[MIG6] = 5 \times 10^4 \text{ cell}^{-1}$ (H1666) or $1.2 \times 10^5 \text{ cell}^{-1}$ (PC9) and $[CBL] = 1 \times 10^5 \text{ cell}^{-1}$) and setting f_r to experimentally determined values.

Supplemental Table 1. Model equations for individual species.

Species Number	Model Species	ODE	Description
1	R	$R1 - R2 - 2 \cdot R3 - R5 - R28 - \text{keb} \cdot R$	EGFR monomer
2	RL	$R2 - R5 - 2 \cdot R7 - R29 - \text{keb} \cdot RL$	EGFR monomer + ligand
3	D	$R3 - R4 - R30 - \text{keb} \cdot D$	EGFR dimer
4	DL	$R4 + R5 - R6 - R18 - R31 - R57 - \text{keb} \cdot DL$	Dimer + ligand
5	DLL	$R6 + R7 - R23 - R32 - R58 - \text{keb} \cdot DLL$	Dimer + 2 ligands
6	M	$-R18 - R23 + R51 + R53$	MIG6
7	DLM	$R18 - R22 - R37 - \text{keb} \cdot DLM$	Dimer + ligand + MIG6
8	DLLM	$R22 + R23 - R39 - \text{keb} \cdot DLLM$	Dimer + 2 ligands + MIG6
9	Ri	$R28 - R41 + \text{keb} \cdot R$	Internalized EGFR
10	RLi	$R29 - R43 + \text{keb} \cdot RL$	Internalized EGFR + ligand
11	Di	$R30 - R44 + \text{keb} \cdot D$	Internalized dimer
12	DLi	$R31 - R45 + \text{keb} \cdot DL$	Internalized dimer + ligand
13	DLLi	$R32 - R46 + \text{keb} \cdot DLL$	Internalized dimer + 2 ligands
14	DLMi	$R37 - R51 + \text{keb} \cdot DLM$	Internalized dimer + ligand + MIG6
15	DLLMi	$R39 - R53 + \text{keb} \cdot DLLM$	Internalized dimer + 2 ligands + MIG6
16	C	$-R57 - R58 + R61 + R62 - R63$	CBL
17	DLC	$R57 - R56 - R59 - \text{keb} \cdot DLC$	Dimer + ligand + CBL
18	DLLC	$R58 + R56 - R60 - \text{keb} \cdot DLLC$	dimer + 2 ligands + CBL
19	DLCi	$R59 - R61 + \text{keb} \cdot DLC$	Internalized dimer + ligand + CBL
20	DLLCi	$R60 - R62 + \text{keb} \cdot DLLC$	Internalized dimer + 2 ligands + CBL
21	Sp	$-R63 - R70 + R69$	Phosphorylated SPRY2
22	CSp	$R63$	CBL + phosphorylated SPRY2
23	kin	$-R68 + R69$	SPRY2 kinase
24	S	$-R68 + R70$	SPRY2
25	kinS	$R68 - R69$	SPRY2 kinase + SPRY2

Supplemental Table 2. Model reactions included in the ODEs in Supplemental Table 1.

Reaction Name	Reaction Equation	Description
R1	$s1$	EGFR synthesis
R2	$f2 \cdot R \cdot L - r2 \cdot RL$	EGF binding
R3	$f3 \cdot R \cdot R - r3 \cdot D$	EGF binding
R4	$2 \cdot f4 \cdot D \cdot L - r4 \cdot DL$	Dimerization
R5	$f5 \cdot R \cdot RL - r5 \cdot DL$	Dimerization
R6	$f6 \cdot DL \cdot L - 2 \cdot r6 \cdot DLL$	EGF binding
R7	$f7 \cdot RL \cdot RL - r7 \cdot DLL$	Dimerization
R18	$2 \cdot f18 \cdot DL \cdot M - r18 \cdot DLM$	MIG6 binding
R22	$f22 \cdot DLM \cdot L - 2 \cdot r22 \cdot DLLM$	EGF binding
R23	$2 \cdot f23 \cdot DLL \cdot M - r23 \cdot DLLM$	MIG6 binding
R28	$k28 \cdot R - kr \cdot Ri \cdot fru$	Internalization/recycling
R29	$k29 \cdot RL - kr \cdot RLi \cdot fr$	Internalization/recycling
R30	$k30 \cdot D - kr \cdot Di \cdot fru$	Internalization/recycling
R31	$k31 \cdot DL - kr \cdot DLi \cdot fr$	Internalization/recycling
R32	$k32 \cdot DLL - kr \cdot DLLi \cdot fr$	Internalization/recycling
R37	$k37 \cdot DLM - kr \cdot DLMi \cdot fr$	Internalization/recycling
R39	$k39 \cdot DLLM - kr \cdot DLLMi \cdot fr$	Internalization/recycling
R41	$kd \cdot Ri \cdot (fdu)$	Degradation
R43	$kd \cdot RLi \cdot (fd)$	Degradation
R44	$kd \cdot Di \cdot (fdu)$	Degradation
R45	$kd \cdot DLi \cdot (fd)$	Degradation
R46	$kd \cdot DLLi \cdot (fd)$	Degradation
R51	$kd \cdot DLMi \cdot (fd)$	Degradation
R53	$kd \cdot DLLMi \cdot (fd)$	Degradation
R56	$f56 \cdot DLC \cdot L - 2 \cdot r56 \cdot DLLC$	EGF binding
R57	$2 \cdot f57 \cdot DL \cdot C - r57 \cdot DLC$	CBL binding
R58	$2 \cdot f58 \cdot DLL \cdot C - r58 \cdot DLLC$	CBL binding
R59	$k59 \cdot DLC - kr \cdot DLCi \cdot fr$	Internalization/recycling
R60	$k60 \cdot DLLC - kr \cdot DLLCi \cdot fr$	Internalization/recycling
R61	$kd \cdot DLCi \cdot (fd)$	Degradation
R62	$kd \cdot DLLCi \cdot (fd)$	Degradation
R63	$f63 \cdot C \cdot Sp - r63 \cdot CSp$	CBL binding
R68	$f68 \cdot S \cdot kin \cdot (\text{Ligand-bound EGFR dimers/total EGFR}) - r68 \cdot kinS$	SPRY2/kinase binding
R69	$f69 \cdot kinS$	SPRY2 phosphorylation
R70	$r70 \cdot Sp$	SPRY2 dephosphorylation

Supplemental Table 3. Parameters for model equations.

Parameter	Description	Typical Value
s1	EGFR synthesis	0 s^{-1}
f2, f4	$k_{on,L}$	$1 \times 10^6 \text{ M}^{-1} \text{ s}^{-1}$
f3, f5	k_{+dim}	$2.6 \times 10^{-8} \text{ cell s}^{-1}$
f6, f22, f56	$k_{on,L2}$	$1 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$
f7	k_{+dim2}	$2.6 \times 10^{-5} \text{ cell s}^{-1}$
f18, f23	$k_{on,M}$	$2 \times 10^{-5} \text{ cell s}^{-1}$
r2, r4, r6, r22, r56	$k_{off,L}$	$2.7 \times 10^{-3} \text{ s}^{-1}$
r3, r5, r7	k_{-dim}	$1 \times 10^{-1} \text{ s}^{-1}$
r18, r23	$k_{off,M}$	1 s^{-1}
keb	$k_{i,basal}$	$3.8 \times 10^{-4} \text{ s}^{-1}$
k28	R internalization	0
k29	RL internalization	0
k30	D internalization	0
k31, k32	Other internalization	$k_{i,other}$ (fitted)
k37, k39	MIG6 internalization	$k_{i,MIG6}$ (fitted)
k59, k60	CBL internalization	$k_{i,CBL}$ (fitted)
kd	k_{deg}	$6 \times 10^{-4} \text{ s}^{-1}$
kr	k_{rec}	$3.4 \times 10^{-3} \text{ s}^{-1}$
fr	f_r	0.5
fru	$f_{r, unbound}$	1
f57, f58	$k_{on,C}$	$4 \times 10^{-6} \text{ cell s}^{-1}$
r57, r58	$k_{off,C}$	1 s^{-1}
f63	$k_{on,S}$	$1 \times 10^{-5} \text{ cell s}^{-1}$
r63	$k_{off,S}$	$1 \times 10^{-1} \text{ s}^{-1}$
f68	SPRY2/kinase k_{on}	$1 \times 10^{-5} \text{ cell s}^{-1}$
r68	SPRY2/kinase k_{off}	$1 \times 10^{-1} \text{ s}^{-1}$
f69	SPRY2 phosphorylation k_{cat}	$1 \times 10^{-1} \text{ s}^{-1}$
r70	SPRY2 dephosphorylation	$1 \times 10^{-3} \text{ s}^{-1}$

Supplemental Table 4. Parameter values based on literature.

Parameter	Value	Reference
$k_{on,L}$ [$M^{-1}s^{-1}$]	1×10^6	Berkers 1991, Felder 1992, French 1995 ³⁻⁵
$k_{off,L}$ [s^{-1}]	2.7×10^{-3}	Berkers 1991, Felder 1992, French 1995 ³⁻⁵
$k_{on,L2}$ [$M^{-1}s^{-1}$]	1×10^5	Berkers 1991, Felder 1992, Macdonald-Obermann 2009 ^{3, 4, 6}
k_{+dim} [cell s^{-1}]	2.6×10^{-8}	Macdonald-Obermann 2009 ⁴
k_{+dim2} [cell s^{-1}]	2.6×10^{-5}	Kholodenko 1999, Schoeberl 2009, Monast 2012 ⁷⁻⁹
k_{-dim} [s^{-1}]	1×10^{-1}	Kholodenko 1999, Schoeberl 2009 ^{8, 9}
k_{deg} [s^{-1}]	6×10^{-4}	Hendriks 2003, Hendriks 2006, Schoeberl 2009 ⁹⁻¹¹
k_{rec} [s^{-1}]	3.4×10^{-3}	Hendriks 2003, Hendriks 2006, Schoeberl 2009 ⁹⁻¹¹
Cell volume [L]	5.2×10^{-13}	Calculated
H1666 f_r	0.574	Walsh 2013 ¹
PC9 f_r	0.899	Walsh 2013 ¹

Supplemental Table 5. Estimated parameter values and initial model species concentrations.

Parameter	H1666	PC9	Reference
MIG6 [cell ⁻¹]	1.2×10 ⁵	5×10 ⁴	Estimated and western blotting ¹
SPRY2 [cell ⁻¹]	5×10 ⁴	5×10 ⁴	Estimated and western blotting ¹
CBL [cell ⁻¹]	1×10 ⁵	1×10 ⁵	Estimated
EGFR [cell ⁻¹]	6×10 ⁵	8×10 ⁵	Based on ¹²⁵ I-EGF binding and western blotting ¹
EGFR (SPRY2 KD) [cell ⁻¹]	3.6×10 ⁵	4×10 ⁵	Walsh 2013 ¹
EGFR (SPRY2 KD+EGFR) [cell ⁻¹]	1.2×10 ⁶	8×10 ⁵	Walsh 2013 ¹
SPRY2 kinase [cell ⁻¹]	1×10 ⁵	1×10 ⁵	Estimated
$k_{i,basal}$ [s ⁻¹]	3.8×10 ⁻⁴	3.8×10 ⁻⁴	fitted
$k_{on,C}$ [cell s ⁻¹]	4×10 ⁻⁶	4×10 ⁻⁶	Hsieh 2010, Ng 2008, Nguyen 2000 ¹²⁻¹⁴
$k_{off,C}$ [s ⁻¹]	1	1	Hsieh 2010, Ng 2008, Nguyen 2000 ¹²⁻¹⁴
$k_{on,M}$ [cell s ⁻¹]	2×10 ⁻⁵	2×10 ⁻⁵	Zhang 2007 ¹⁵
$k_{off,M}$ [s ⁻¹]	1	1	Zhang 2007 ¹⁵
$k_{on,S}$ [cell s ⁻¹]	1×10 ⁻⁵	1×10 ⁻⁵	Ng 2008 ¹²
$k_{off,S}$ [s ⁻¹]	1×10 ⁻¹	1×10 ⁻¹	Ng 2008 ¹²
SPRY2/kinase binding	$k_{on} = 1 \times 10^{-5} \text{ cell s}^{-1};$ $k_{off} = 1 \times 10^{-1} \text{ s}^{-1}$	$k_{on} = 1 \times 10^{-5} \text{ cell s}^{-1};$ $k_{off} = 1 \times 10^{-1} \text{ s}^{-1}$	Northrup 1992, Kholodenko 1999, 8, 16
SPRY2 phosphorylation k_{cat} [s ⁻¹]	1×10 ⁻¹	1×10 ⁻¹	Estimated based on Mason 2004 ²
SPRY2 dephosphorylation [s ⁻¹]	1×10 ⁻³	1×10 ⁻³	Estimated based on Mason 2004 ²

Supplemental Table 6. Normalized experimental k_e data.

Measurement	H1666	PC9
k_e (min ⁻¹) control	0.170	0.058
k_e (min ⁻¹) MIG6 KD	0.116	0.034
k_e (min ⁻¹) SPRY2 KD	0.219	0.091
k_e (min ⁻¹) MIG6/SPRY2 KD	0.149	0.038
k_e (min ⁻¹) SPRY2 KD + EGFR	0.148	0.058

Supplemental Table 7. Full results of local parameter sensitivity analysis.

H1666 parameter	Normalized sensitivity	PC9 parameter	Normalized sensitivity
$k_{off,kinS}$	4.65×10^{-5}	$k_{i,other}$	4.41×10^{-7}
k_{dephos}	0.00117	k_{dephos}	1.96×10^{-5}
$k_{on,kinS}$	0.00132	$k_{cat,S}$	5.65×10^{-5}
$k_{cat,S}$	0.00180	$k_{off,kinS}$	8.73×10^{-5}
$k_{on,L2}$	0.00237	$k_{on,kinS}$	0.000451
$f_{r,unbound}$	0.00363	$k_{on,S}$	0.000481
$k_{off,L}$	0.00720	$k_{off,S}$	0.000500
k_{+dim2}	0.00987	$k_{on,C}$	0.00192
k_{+dim}	0.0187	$k_{off,C}$	0.00222
$k_{on,S}$	0.0226	$k_{on,L2}$	0.00340
$k_{off,S}$	0.0254	k_{+dim}	0.00467
k_{-dim}	0.0270	$f_{r,unbound}$	0.00513
k_{deg}	0.0384	k_{-dim}	0.00620
$k_{off,M}$	0.0600	$k_{off,L}$	0.00665
$k_{on,M}$	0.0602	k_{+dim2}	0.00755
$k_{i,basal}$	0.110	k_{deg}	0.0414
$k_{off,C}$	0.127	$k_{i,CBL}$	0.0505
$k_{on,C}$	0.1303	$k_{on,M}$	0.138
$k_{i,other}$	0.198	$k_{off,M}$	0.139
f_r	0.207	f_r	0.208
k_{rec}	0.247	k_{rec}	0.252
$k_{i,CBL}$	0.273	$k_{i,basal}$	0.265
$k_{on,L}$	0.284	$k_{on,L}$	0.290
$k_{i,MIG6}$	0.302	$k_{i,MIG6}$	0.629

References:

1. A. M. Walsh, M. J. Lazzara, Regulation of EGFR trafficking and cell signaling by Sprouty2 and MIG6 in lung cancer cells. *J Cell Sci* 2013, *126*. 4339-48 .
2. J. M. Mason, D. J. Morrison, B. Bassit, M. Dimri, H. Band, J. D. Licht, I. Gross, Tyrosine phosphorylation of Sprouty proteins regulates their ability to inhibit growth factor signaling: a dual feedback loop. *Mol Biol Cell* 2004, *15*. 2176-2188.
3. J. A. Berkers, P. M. van Bergen en Henegouwen, J. Boonstra, Three classes of epidermal growth factor receptors on HeLa cells. *J Biol Chem* 1991, *266*. 922-927.
4. S. Felder, J. LaVin, A. Ullrich, J. Schlessinger, Kinetics of binding, endocytosis, and recycling of EGF receptor mutants. *J Cell Biol* 1992, *117*. 203-212.
5. A. R. French, D. K. Tadaki, S. K. Niyogi, D. A. Lauffenburger, Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction. *J Biol Chem* 1995, *270*. 4334-4340.
6. J. L. Macdonald-Obermann, L. J. Pike, The intracellular juxtamembrane domain of the epidermal growth factor (EGF) receptor is responsible for the allosteric regulation of EGF binding. *J Biol Chem* 2009, *284*. 13570-13576.
7. C. S. Monast, C. M. Furcht, M. J. Lazzara, Computational analysis of the regulation of EGFR by protein tyrosine phosphatases. *Biophys J* 2012, *102*. 2012-2021.
8. B. N. Kholodenko, O. V. Demin, G. Moehren, J. B. Hoek, Quantification of short term signaling by the epidermal growth factor receptor. *J Biol Chem* 1999, *274*. 30169-30181.
9. B. Schoeberl, E. A. Pace, J. B. Fitzgerald, B. D. Harms, L. Xu, L. Nie, B. Linggi, A. Kalra, V. Paragas, R. Bukhalid, V. Grantcharova, N. Kohli, K. A. West, M. Leszczyniecka, M. J. Feldhaus, A. J. Kudla, U. B. Nielsen, Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. *Sci Signal* 2009, *2*. ra31.
10. B. S. Hendriks, G. J. Griffiths, R. Benson, D. Kenyon, M. Lazzara, J. Swinton, S. Beck, M. Hickinson, J. M. Beusmans, D. Lauffenburger, D. de Graaf, Decreased internalisation of erbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib. *Syst Biol (Stevenage)* 2006, *153*. 457-466.
11. B. S. Hendriks, H. S. Wiley, D. Lauffenburger, HER2-mediated effects on EGFR endosomal sorting: analysis of biophysical mechanisms. *Biophys J* 2003, *85*. 2732-2745.
12. C. Ng, R. A. Jackson, J. P. Buschdorf, Q. Sun, G. R. Guy, J. Sivaraman, Structural basis for a novel intrapeptidyl H-bond and reverse binding of c-Cbl-TKB domain substrates. *EMBO J* 2008, *27*. 804-816.
13. J. T. Nguyen, M. Porter, M. Amoui, W. T. Miller, R. N. Zuckermann, W. A. Lim, Improving SH3 domain ligand selectivity using a non-natural scaffold. *Chem Biol* 2000, *7*. 463-473.
14. M. Y. Hsieh, S. Yang, M. A. Raymond-Stinz, J. S. Edwards, B. S. Wilson, Spatio-temporal modeling of signaling protein recruitment to EGFR. *BMC Syst Biol* 2010, *4*. 57.
15. X. Zhang, K. A. Pickin, R. Bose, N. Jura, P. A. Cole, J. Kuriyan, Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. *Nature* 2007, *450*. 741-744.
16. S. H. Northrup, H. P. Erickson, Kinetics of protein-protein association explained by Brownian dynamics computer simulation. *Proc Natl Acad Sci USA* 1992, *89*. 3338-3342.